Third Point’s 10x Genomics TXG Stock Holding History

Third Point’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-123,268	Closed	-$15.4M	–	78
2020 Q3	$15.4M	Buy	+123,268	New	+$12.9M	0.15%	41

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCAV

Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

VMV

Venrock Management VI Palo Alto, California $47.6M AUM 45.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Third Point's TXG Position: Q4 2020 in Review

Third Point sold out of 10x Genomics (TXG) in Q4 2020, closing a stake of 123,268 shares — an estimated $15.4M sold.

Third Point first reported a position in TXG in Q3 2020 and held it in 1 quarter. The position peaked at $15.4M in Q3 2020. 304 funds tracked by Wall St. Rank hold TXG as of Q4 2020.

Third Point reported no remaining 10x Genomics position as of Q4 2020 after selling out during the quarter.
Third Point sold 123,268 10x Genomics shares in Q4 2020, an estimated $15.4M.
Third Point first reported a position in 10x Genomics in Q3 2020 and held it in 1 quarter.
Third Point's 10x Genomics position peaked at $15.4M in Q3 2020.
304 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2020.

Based on Third Point's 13F filing for Q4 2020, filed 16 Feb 2021.